Robert Miller

Dr. Miller investigates methods to reduce neuroinflammation and slow the progression of amyotrophic lateral sclerosis (ALS). Ongoing clinical studies initiated by Dr. Miller and colleagues at CPMC include trials of various pharmacotherapies that have shown promise in slowing the progression of ALS; device trials; a study of the NeuRX Diaphragm Pacing System to support patients with diaphragm weakness; and observational studies on factors that affect ALS disease progression. In 2014, Dr. Miller and colleagues at CPMC will collaborate with Cedars-Sinai Regenerative Medicine Institute on new stem cell and gene therapy techniques to treat ALS patients.